Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
- Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuationon March 18, 2024 at 10:03 pm
JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and...
- Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Modelon March 18, 2024 at 7:03 pm
March 18, 2024 -- Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), successfully alleviated pain and inflammation in a rodent model of endometriosis, according to researchers funded by the National Institutes of Health (NIH). They chose the...
- myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trialson March 15, 2024 at 9:03 am
NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front. myTomorrows is a global health technology company shaping the future landscape of...
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDSon March 14, 2024 at 9:03 pm
FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies,...
- Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromeson March 14, 2024 at 3:03 am
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of...
- Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorderon March 13, 2024 at 11:03 pm
TORONTO--(BUSINESS WIRE) March 13, 2024 --Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
- FDA Revises Letter of Authorization for the Emergency Use Authorization for Paxlovidon March 13, 2024 at 10:01 pm
Update: March 13, 2024 -- EUA-labeled Paxlovid is no longer authorized for emergency use, regardless of the labeled or extended expiration date. For both NDA-approved and EUA-authorized uses, only NDA-labeled Paxlovid may be dispensed. Today’s...
- PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemiaon March 13, 2024 at 4:03 am
13 March 2024 -- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug...
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)on March 13, 2024 at 3:03 am
LONDON--(BUSINESS WIRE) March 13, 2024 -- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing...
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopeniaon March 13, 2024 at 12:03 am
OSAKA, Japan, and CAMBRIDGE, Massachusetts, March 13, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and...
- Delta-8-THC Use Reported by 11% of 12th Graders in 2023on March 12, 2024 at 9:03 pm
March 12, 2024 -- Use of the psychoactive cannabis product is higher in states without existing delta-8 regulations or cannabis legalization, NIH-funded study finds. Approximately 11% of 12th-grade students across the United States reported...
- NIH Opens Long COVID Trials to Evaluate Treatments for Autonomic Nervous System Dysfunctionon March 12, 2024 at 9:03 pm
March 12, 2024 -- Part of NIH’s RECOVER Initiative, trials will test at least three treatments for symptoms such as fast heart rate, dizziness and fatigue. People 18 years of age and older who are interested in learning more about these...
- EmpowerPharm Awaits Phase II Clinical Trial On Ground Breaking Cannabidiol Treatment To Manage Social Anxiety Disorderon March 11, 2024 at 9:03 pm
Burlington, ON March 11, 2024 – EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II clinical trial assessing the efficacy of pharmaceutical-grade Cannabidiol (CBD) for Social...
- Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depoton March 11, 2024 at 1:03 am
March 11, 2024 -- Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the U.S. Food and Drug Administration (FDA). The Companies are...
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted To TERN-701 For The Treatment Of Chronic Myeloid Leukemiaon March 11, 2024 at 12:03 am
FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product...
- More Than Two-Thirds of People with Atopic Dermatitis and Skin of Color Experienced Skin Improvement in a First-of-its-Kind Lebrikizumab Studyon March 10, 2024 at 8:03 pm
INDIANAPOLIS, March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly...
- Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesityon March 10, 2024 at 5:03 am
CAMBRIDGE, Mass., March 9, 2024. Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2...
- New Data Shows JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Yearon March 9, 2024 at 8:03 pm
SAN DIEGO (March 9, 2024) – Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide...
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemabon March 8, 2024 at 11:03 pm
INDIANAPOLIS, March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS)...
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALSon March 8, 2024 at 4:03 am
CAMBRIDGE, Mass.--(BUSINESS WIRE) March 08, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled...